COMP <GO>
PBYI vs ABBV // DIVIDEND YIELD & FCF PAYOUT SAFETY
Puma Biotechnology Inc (NASDAQ) VS. AbbVie Inc. (NYSE) • 15-METRIC TALLY: PBYI 7
— ABBV 6
▲ DIVIDEND YIELD & FCF PAYOUT SAFETY LEADER: ABBV
LAST: $10.54 (-0.75%) • MKT CAP: $544.1M
dividend-safety
0.00%
LAST: $290.79 (+1.68%) • MKT CAP: $513.86B
dividend-safety
2.27%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (PBYI VS. ABBV)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | PBYI | ABBV | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 74.50% | 70.20% | +4.30 | PBYI | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 29.30% | 29.00% | +0.30 | PBYI | /roic <GO> |
| EV/EBITDA & P/E Valuation | 13.8x | 33.3x | -19.50 | PBYI | /valuation <GO> |
| Free Cash Flow Yield | 7.67% | 3.47% | +4.20 | PBYI | /fcf-yield <GO> |
| Operating Margin | 16.30% | 24.60% | -8.30 | ABBV | /operating-margins <GO> |
| Net Profit Margin | 13.60% | 6.90% | +6.70 | PBYI | /net-margins <GO> |
| Revenue Growth (YoY) | -0.90% | 8.60% | -9.50 | ABBV | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety ACTIVE | 0.00% | 2.27% | -2.27 | ABBV | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 0.20 | 5.33 | -5.13 | ABBV | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 7/9 | +1.00 | PBYI | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 52.9 | 65.1 | -12.19 | ABBV | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 1.15 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 16.3x | 113.1x | -96.80 | PBYI | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $544.1M | $513.86B | -$513.32B | ABBV | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | PBYI REV | ABBV REV | PBYI GROSS % | ABBV GROSS % | PBYI FCF | ABBV FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $228.4M | $61.16B | 74.5% | 70.2% | $41.7M | $17.82B |
| FY 2024 | $230.5M | $56.33B | 72.1% | 70.0% | $38.9M | $17.83B |
| FY 2023 | $235.6M | $54.32B | — | — | $27.0M | $20.39B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
PBYI // BETA —
ABBV // BETA 1.15